---
layout: post
title: "机会速递｜A股三大指数齐涨！CRO概念股崛起！这些个股有机会！(附A股通标的)"
date: 2022-05-27 11:13:21 +0800
categories: hafuzhengquan
tags: 哈富证券新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_Adv_Module_Start --><center style="text-align:left;"><div class="em_adv_mods" type="1" tag="31" name="%u54C8%u5BCC-%u5F00%u6237-A%u80A1" style="display:none;"> </div> </center><!-- EM_Adv_Module_End --><p>周五(5月27日)A股集体高开，截至发稿，上证指数、深证成指、创业板指齐涨。美国务卿发表对华政策演讲，称决心避免“新冷战”，此外，上海企业复工复产局面持续向好。</p><h3 class="emh3"><strong>CRO概念股崛起！</strong></h3><p><strong><span style="color:#ea5504;"><span></span>板块利好</span></strong></p><p>消息面上，国务院办公厅印发《深化医药卫生体制改革2022年重点工作任务》提到，强化药品供应保障能力。</p><p><strong><span style="color:#ea5504;">个股机会聚焦</span></strong></p><p><strong>凯莱英(002821.SZ)</strong></p><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002821&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002821_0" data-code="K 002821|0|2" data-code2="K 002821|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><!-- EM_StockImg_End --><p><strong>机会解读</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220527101616072616720">凯莱英是为数不多的可以买入的CXO标的</a></p><p><a href="https://caifuhao.eastmoney.com/news/20220527101517666970840">今年最严重低估的板块CXO今天为何大涨？</a></p><p><strong>行业分析</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220527102226191931270">西南证券：建议关注产业链布局一体化的平台型CXO企业 推荐凯莱英等</a></p><p><strong>业绩利好</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220520104325106426320">辉瑞特效药销售爆发，凯莱英今年净利润超50亿</a></p><p><strong>药明康德(603259.SH)</strong></p><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/sh603259.html" data-code="603259|1|1" data-code2="603259|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.603259&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 603259_0" data-code="K 603259|1|1" data-code2="K 603259|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p><strong>机会解读</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220527102028169714540">年中总结与展望：继续坚定看好cxo跟cro相关企业 例如药明康德</a></p><p><a href="https://caifuhao.eastmoney.com/news/20220526071247126127240">药明康德2022-23年业绩估算：净利润超110亿和150亿</a></p><p><strong>行业分析</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220527103634061718020">深度报告：解析医药CRO产业链及行业趋势 药明康德等具较强市场竞争力</a></p><p><strong>股友热议</strong></p><p><a href="https://caifuhao.eastmoney.com/news/20220526223434213223540">药明康德技术指标来看 有形成底背离的迹象 期待短期反弹</a></p><p class="em_media">（文章来源：哈富证券）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205272394280834>

[返回哈富证券新闻](//finews.withounder.com/category/hafuzhengquan.html)｜[返回首页](//finews.withounder.com/)